Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Depreciation & Amortization (CF) (2020 - 2025)

Historic Depreciation & Amortization (CF) for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to $22817.0.

  • Gain Therapeutics' Depreciation & Amortization (CF) rose 542.44% to $22817.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $87112.0, marking a year-over-year increase of 87.9%. This contributed to the annual value of $84071.0 for FY2024, which is 58.87% up from last year.
  • As of Q3 2025, Gain Therapeutics' Depreciation & Amortization (CF) stood at $22817.0, which was up 542.44% from $22328.0 recorded in Q2 2025.
  • In the past 5 years, Gain Therapeutics' Depreciation & Amortization (CF) registered a high of $23589.0 during Q4 2023, and its lowest value of $2158.0 during Q2 2021.
  • In the last 5 years, Gain Therapeutics' Depreciation & Amortization (CF) had a median value of $20239.0 in 2023 and averaged $16479.3.
  • In the last 5 years, Gain Therapeutics' Depreciation & Amortization (CF) skyrocketed by 82775.72% in 2022 and then tumbled by 967.4% in 2024.
  • Over the past 5 years, Gain Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $5788.0 in 2021, then soared by 212.89% to $18110.0 in 2022, then soared by 30.25% to $23589.0 in 2023, then decreased by 9.67% to $21307.0 in 2024, then grew by 7.09% to $22817.0 in 2025.
  • Its Depreciation & Amortization (CF) was $22817.0 in Q3 2025, compared to $22328.0 in Q2 2025 and $20660.0 in Q1 2025.